EyeTect: Starting Over with OMT for Neuro Intensive Care
Executive Summary
For its first three years, EyeTect, developers of an innovative technology using ocular microtremors to monitor brain function, was the very model of efficient device development. With less than $1 million raised, the company developed a working device, funded several important clinical studies, and even got FDA clearance. But when an anticipated marketing agreement with a well-established competitor fell through, the company all but shut down. Now EyeTect is starting again, with a new managment team and a new target application.